Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.42 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578791 | 0.90 | MAPK1 (0.45) | SMN1; SMN2ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL31057887 | 0.85 | SHMT2 (0.44) | SMN1; SMN2ALDH1A1SHMT2SHMT1KDM4E | |
| SCHEMBL31578816 | 0.83 | ACKR3 (0.47) | SHMT2SHMT1 | |
| SCHEMBL31578724 | 0.82 | SHMT2 (0.53) | SMN1; SMN2ALDH1A1SHMT2SHMT1KDM4E | |
| SCHEMBL31578820 | 0.81 | MAPT (0.44) | SMN1; SMN2ALDH1A1KDM4EMAPTTP53 | |
| SCHEMBL31057813 | 0.80 | MAPT (0.42) | SMN1; SMN2ALDH1A1SHMT2SHMT1KDM4E | |
| SCHEMBL31578832 | 0.78 | SHMT2 (0.54) | ALDH1A1SHMT2SHMT1KDM4EMAPT | |
| SCHEMBL31578923 | 0.78 | SHMT2 (0.55) | SMN1; SMN2ALDH1A1SHMT2SHMT1KDM4E | |
| SCHEMBL31578879 | 0.77 | SHMT2 (0.48) | SMN1; SMN2ALDH1A1SHMT2SHMT1KDM4E | |
| SCHEMBL31578885 | 0.77 | SHMT2 (0.52) | ALDH1A1SHMT2SHMT1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163075-A1 | HETEROBIFUNCTIONAL TARGETED PROTEIN DEGRADERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163075-A1 | HETEROBIFUNCTIONAL TARGETED PROTEIN DEGRADERS | KLHDC2, KLHL6, KLHL20 | SMN1; SMN2 3838/4885ALDH1A1 2481/4885SHMT2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.